drugset / Trial / NCT03596762

A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

NCT03596762

Phase 2 Completed 199 enrolled Bayer Nerre Therapeutics Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the effectiveness of BAY3427080 (NT-814), taken once a day, in the treatment of troublesome post-menopausal symptoms.

Timeline

Start
2018-11-20
Primary completion
2019-11-21
Completion
2019-11-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Elinzanetant Small molecule 40 mg
Subject Elinzanetant Small molecule 80 mg
Subject Elinzanetant Small molecule 120 mg
Subject Elinzanetant Small molecule 160 mg

Indications

No indication recorded.